Illuccix Receives European Approval
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix JP Morgan Healthcare Conference 2025 Presentation
- Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
- Presentation to Accompany Biologics Platform Acquisition
- TLX to Acquire Next-Gen Therapeutics and Biologics Platform
- Presentation to Accompany FAP-Targeting Acquisition
Later from Telix Pharmaceuticals
- Telix Completes Acquisition of RLS (USA) Inc
- Telix Completes Acquisition of Tx Assets, Biologics Platform
- Illuccix Approved in the United Kingdom
- Appendix 4E and 2024 Annual Report
- 2024 Full Year Results Announcement
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals